Yourgene Health PLC - Scheme of Arrangement becomes Effective
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
FOR IMMEDIATE RELEASE
RECOMMENDED CASH OFFER
for
Yourgene Health plc ("Yourgene")
by
Novacyt UK Holdings Limited
(a wholly-owned subsidiary of Novacyt S.A. ("Novacyt"))
to be effected by means of a Scheme of Arrangement
under Part 26 of the Companies Act 2006
Scheme of Arrangement becomes Effective
On
The circular in relation to the Scheme was published on
Capitalised terms used in this Announcement shall, unless otherwise defined, have the same meaning as set out in Part VII of the Scheme Document. All references to times in this announcement are to
On
Further to the announcement made by Yourgene on
Settlement
Scheme Shareholders on the register of members at the Scheme Record Time, being
Settlement of the consideration to which each Scheme Shareholder is entitled will, for Scheme Shareholders holding Scheme Shares in certificated form, be effected by way of the despatch of cheques, or, for Scheme Shareholders holding Scheme Shares in uncertificated form, through the crediting of CREST accounts (or by any other method approved by the Panel) as soon as practicable and in any event not later than
In the case of Yourgene Shares held by participants under the SIP, settlement of consideration will be effected through payment by Yourgene as soon as practicable following receipt by Yourgene of payment in respect of such consideration from the trustee of the SIP, in accordance with the letters sent to such participants by the trustee of the SIP.
As a result of the Scheme becoming Effective, share certificates in respect of Yourgene Shares will cease to be valid evidence of title and entitlements to Yourgene Shares held in uncertificated form within the CREST system will be cancelled.
Suspension of trading and cancellation of admission to trading on AIM
Dealings in Yourgene Shares on AIM were suspended with effect from
Dealing disclosures
Yourgene is no longer in an "Offer Period" as defined in the Takeover Code and accordingly the dealing disclosure requirements previously notified to Yourgene Shareholders no longer apply.
Enquiries:
|
Yourgene |
|
|
|
c/o Stifel |
|
Stifel (Rule 3 Adviser and Sole Financial Adviser to Yourgene) |
|
|
|
Tel: +44 (0) 20 7710 7600 |
|
Cairn (Nominated Adviser to Yourgene) |
|
|
|
Tel: +44 (0) 20 7213 0880 |
|
Walbrook PR Limited (Media and Investor Relations for Yourgene) |
|
|
|
Tel: +44 (0) 20 7933 8780 or yourgene@walbrookpr.com Mob: +44 (0) 7407 804 654 / +44 (0) 7584 391 303 |
|
Novacyt |
|
|
|
c/o Numis |
|
Numis (Financial Adviser and Joint Broker to Novacyt and Financial Adviser to Novacyt UK) |
|
|
|
Tel: +44 (0) 20 7260 1000 |
|
S.P. Angel Corporate Finance LLP (Nominated Adviser and Joint Broker to Novacyt) |
|
|
|
Tel: +44 (0) 20 3470 0470 |
|
Walbrook PR Limited (Media and Investor Relations for Novacyt) |
|
|
|
Tel: +44 (0) 20 7933 8780 or novacyt@walbrookpr.com |
Addleshaw Goddard LLP is providing legal advice to Yourgene.
Stephenson Harwood LLP is providing legal advice to Novacyt and Novacyt UK.
Important Notices
Numis Securities Limited ("Numis"), which is authorised and regulated in the
S.P. Angel Corporate Finance LLP ("SP Angel"), which is authorised and regulated in the
Stifel Nicolaus Europe Limited ("Stifel"), which is authorised and regulated in the
Cairn Financial Advisers LLP ("Cairn"), which is authorised and regulated in the
This Announcement is for information purposes only and is not intended to and does not constitute, or form any part of, an offer to sell or subscribe for or any invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the Acquisition or otherwise.
The statements contained in this Announcement are made as at the date of this Announcement, unless some other time is specified in relation to them, and service of this Announcement shall not give rise to any implication that there has been no change in the facts set forth in this Announcement since such date.
Publication on website
A copy of this Announcement and the documents required to be published pursuant to Rules 26.1 and 26.2 of the Takeover Code will be made available (subject to certain restrictions relating to persons resident in Restricted Jurisdictions), free of charge, on Yourgene's website at https://yourgenehealth.com/our-investors/offer-for-yourgene-health-plc/ and on Novacyt's website at https://novacyt.com/investors/ by no later than 12.00 noon (
Neither the contents of these websites nor the content of any other website accessible from hyperlinks on such websites is incorporated into, or forms part of, this Announcement.
Requesting hard copies
In accordance with Rule 30.3 of the Takeover Code, Yourgene Shareholders may request a hard copy of this Announcement (and any information incorporated by reference into this Announcement), free of charge, by contacting the Yourgene's registrar, Link Group, by: (i) submitting a request in writing to Link Group, Corporate Actions,
For persons who receive a copy of this Announcement in electronic form or via a website notification, a hard copy of this Announcement will not be sent unless so requested.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE